Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 13;59(2):354.
doi: 10.3390/medicina59020354.

Urinary microRNA in Diabetic Kidney Disease: A Literature Review

Chin-Chan Lee  1 , Chia-Chun Chen  2   3 , Cheng-Kai Hsu  1 , Yih-Ting Chen  1 , Chun-Yu Chen  1 , Kai-Jie Yang  1 , Ming-Jui Hung  4 , I-Wen Wu  1   5
Affiliations
Review

Urinary microRNA in Diabetic Kidney Disease: A Literature Review

Chin-Chan Lee et al. Medicina (Kaunas). .

Abstract

Diabetic kidney disease is the most common primary disease of end-stage kidney disease globally; however, a sensitive and accurate biomarker to predict this disease remains awaited. microRNAs are endogenous single-stranded noncoding RNAs that have intervened in different post-transcriptional regulations of various cellular biological functions. Previous literatures have reported its potential role in the pathophysiology of diabetic kidney disease, including regulation of Transforming Growth Factor-β1-mediated fibrosis, extracellular matrix and cell adhesion proteins, cellular hypertrophy, growth factor, cytokine production, and redox system activation. Urinary microRNAs have emerged as a novel, non-invasive liquid biopsy for disease diagnosis. In this review, we describe the available experimental and clinical evidence of urinary microRNA in the context of diabetic kidney disease and discuss the future application of microRNA in routine practice.

Keywords: diabetes mellitus; diabetic kidney disease; exosomes; microRNA; urinary.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of literature search and selection.
See this image and copyright information in PMC

References

    1. WHO Improving Health Outcomes of People with Diabetes Mellitus: Target Setting to Reduce the Global Burden of Diabetes Mellitus by 2030. 2021. [(accessed on 30 October 2022)]. Available online: https://www.who.int/publications/m/item/improving-health-outcomes-of-peo....
    1. Federation I.D. IDF Diabetes Atlas. Ninth edition 2019. [(accessed on 13 September 2021)]. Available online: www.diabetesatlas.org.
    1. Alicic R.Z., Cox E.J., Neumiller J.J., Tuttle K.R. Incretin drugs in diabetic kidney disease: Biological mechanisms and clinical evidence. Nat. Rev. Nephrol. 2021;17:227–244. doi: 10.1038/s41581-020-00367-2. - DOI - PubMed
    1. System U.S.R.D. 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda, MD, USA: 2020.
    1. Webster A.C., Nagler E.V., Morton R.L., Masson P. Chronic Kidney Disease. Lancet. 2017;389:1238–1252. doi: 10.1016/S0140-6736(16)32064-5. - DOI - PubMed